- Data analytics company Ixico said Tuesday annual losses more than halved supported by strong revenue in its core imaging business.

For the year ended 30 September 2018, pre-tax losses narrowed to £0.793m from £1.91bn a year earlier and revenue increased by 32% to a record £5.4m.

The uptick in revenue was supported by growth from clinical trials services, Assessa PML, wearables projects and licensing revenue.

The core imaging business growth was further enhanced by strong first year revenue from the company's wearable biosensor contracts and continuation of its Assessa PML programme, the company said.

During the year, the company announced £15m of new and expanded multi-year contracts across a range of therapeutic areas.

'We enter the new year with a healthy orderbook from our blue-chip clients and the Board is confident in meeting our expectations for growth,' the company said.

At 9:00am: [LON:IXI] IXICO plc share price was +3p at 26.5p

Story provided by